Sign up
Log in
12 Health Care Stocks Moving In Monday's Pre-Market Session
Share
Listen to the news

Gainers

  • Indaptus Therapeutics (NASDAQ:INDP) stock increased by 141.3% to $0.65 during Monday's pre-market session. The market value of their outstanding shares is at $4.3 million.
  • Impact BioMedical (AMEX:IBO) shares moved upwards by 104.55% to $0.74. The company's market cap stands at $4.3 million.
  • Cidara Therapeutics (NASDAQ:CDTX) shares moved upwards by 66.84% to $35.07. The company's market cap stands at $272.6 million.
  • Forte Biosciences (NASDAQ:FBRX) stock moved upwards by 40.78% to $20.64. The company's market cap stands at $96.5 million.
  • CARISMA Therapeutics (NASDAQ:CARM) shares moved upwards by 33.18% to $0.59. The market value of their outstanding shares is at $18.4 million.
  • Exelixis (NASDAQ:EXEL) stock increased by 23.13% to $49.71. The market value of their outstanding shares is at $11.0 billion.

Losers

  • Compass Pathways (NASDAQ:CMPS) shares declined by 35.2% to $3.0 during Monday's pre-market session. The company's market cap stands at $433.1 million.
  • SS Innovations (NASDAQ:SSII) shares declined by 21.39% to $5.44. The company's market cap stands at $1.3 billion.
  • Alaunos Therapeutics (NASDAQ:TCRT) shares decreased by 18.19% to $3.51. The market value of their outstanding shares is at $7.0 million.
  • Hims & Hers Health (NYSE:HIMS) shares fell 17.13% to $53.22. The market value of their outstanding shares is at $14.3 billion.
  • Processa Pharmaceuticals (NASDAQ:PCSA) shares fell 15.13% to $0.27. The company's market cap stands at $3.8 million.
  • Innovative Eyewear (NASDAQ:LUCY) shares decreased by 13.32% to $3.06. The market value of their outstanding shares is at $10.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.